

**CLINIC INFORMATION**

Name: Streamline Pathology Laboratory  
Address: 2868 Acton Road Suite 207  
BIRMINGHAM, AL 35243  
Provider: Test, Doctor MD

**PATIENT INFORMATION**

Name: TEST, PATIENT  
DOB: 3/31/1995 Sex: M  
Phone: (777)777-7777  
Address: 456 MAPLE ST  
BIRMINGHAM, AL 35243

**SPECIMEN INFORMATION**

Lab Accession Number: S-11082310130  
Date Collected: 11/08/23 2:26:00 PM  
Date Accessioned: 11/08/2023  
Date Reported: 11/08/2023  
Faxed to: 18777966185

**Controls**

Panel Positive Control <sup>1</sup> PASS  
Panel Negative Control <sup>2</sup> PASS

(1) Positive control is synthetic inactive pathogen  
(2) Negative Control contains primers, probe, and enzymes with no DNA/RNA template  
(3) A "Detected" result indicates the presence of a pathogen (99.99% confidence) above the assay cutoff.

Test Performed	Lab Result (3) (Qualitative Low/Medium/High)	DNA Copy Number	Comments
<b>SUMMARY Gastrointestinal Panel w/ C.Diff Add-On</b>			<b>Collection Type: Stool - Fecal</b>
Clostridium difficile (tcdA/tcdB)	DETECTED - LOW	< 1,000	[11/08/23] * Due to the high prevalence of asymptomatic carriage of toxigenic C. difficile in infants, testing for CDI should never be routinely recommended for neonates or infants 12 months of age or younger with diarrhea  * C. difficile testing should not be routinely performed in children with diarrhea who are 1-2 years of age unless other infectious or noninfectious causes have been excluded  * In children 2 years of age or older, C. difficile testing is recommended for patients with prolonged or worsening diarrhea and risk factors (eg, underlying inflammatory bowel disease or immunocompromising conditions) or relevant exposures (eg, contact with the healthcare system or recent antibiotics)
Norovirus GI/GII	DETECTED	DETECTED	

Clinic Name: Streamline Pathology Laboratory

Patient name: TEST, PATIENT

Lab Director: Robert Thomas, MD

Ver. PP231013.1 Page: 1

Test results must be evaluated with clinical symptoms to diagnose disease. All tests established and validated by Laboratory and not FDA approved unless otherwise indicated.

Methodology statement: Real-time PCR assays are designed to detect pathogens with clinical significance and analytical sensitivity and specificity greater than 99%.

Limitations: While these assays are very sensitive and specific, theoretically these assays could detect pathogens not listed, resulting in a false positive.

In addition, while these assays are very specific, there may be target pathogen sequences with unknown sequence variability which may not be detected, resulting in a false negative result.

**CLINIC INFORMATION**

Name: Streamline Pathology Laboratory  
Address: 2868 Acton Road Suite 207 BIRMINGHAM, AL 35243  
Provider: Test, Doctor MD

**PATIENT INFORMATION**

Name: TEST, PATIENT  
DOB: 3/31/1995 Sex: M  
Phone: (777)777-7777  
Address: 456 MAPLE ST BIRMINGHAM, AL 35243

**SPECIMEN INFORMATION**

Lab Accession Number: S-11082310130  
Date Collected: 11/08/23 2:26:00 PM  
Date Accessioned: 11/08/2023  
Date Reported: 11/08/2023  
Faxed to: 18777966185

Test Performed	Lab Result (3) (Qualitative Low/Medium/High)	DNA Copy Number	Comments
<b>Gastrointestinal Panel w/ C.Diff Add-On</b>			<b>Collection Type: Stool - Fecal</b>
Adenovirus F40/F41	Not Detected	Not Detected	
Astrovirus	Not Detected	Not Detected	
Campylobacter coli/jejuni/lari/upsaliensis	Not Detected	Not Detected	
<b>Clostridium difficile (tcdA/tcdB)</b>	<b>DETECTED - LOW</b>	<b>&lt; 1,000</b>	<p>[11/08/23] * Due to the high prevalence of asymptomatic carriage of toxigenic C. difficile in infants, testing for CDI should never be routinely recommended for neonates or infants 12 months of age or younger with diarrhea</p> <p>* C. difficile testing should not be routinely performed in children with diarrhea who are 1-2 years of age unless other infectious or noninfectious causes have been excluded</p> <p>* In children 2 years of age or older, C. difficile testing is recommended for patients with prolonged or worsening diarrhea and risk factors (eg, underlying inflammatory bowel disease or immunocompromising conditions) or relevant exposures (eg, contact with the healthcare system or recent antibiotics)</p>
Cryptosporidium spp.	Not Detected	Not Detected	
Entamoeba histolytica	Not Detected	Not Detected	
Enterotoxigenic E.coli (ETEC)	Not Detected	Not Detected	
Enteroinvasive E.coli (EIEC)/Shigella spp.	Not Detected	Not Detected	
Shiga-like Toxin producing E.coli (STEC)	Not Detected	Not Detected	
Giardia lamblia	Not Detected	Not Detected	
<b>Norovirus GI/GII</b>	<b>DETECTED</b>	<b>DETECTED</b>	
Rotavirus A	Not Detected	Not Detected	
Salmonella spp.	Not Detected	Not Detected	
Vibrio spp.	Not Detected	Not Detected	
Yersinia enterocolitica	Not Detected	Not Detected	

Clinic Name: Streamline Pathology Laboratory

Patient name: TEST, PATIENT

Lab Director: Robert Thomas, MD

Ver. PP231013.1 Page: 2

Test results must be evaluated with clinical symptoms to diagnose disease. All tests established and validated by Laboratory and not FDA approved unless otherwise indicated.

Methodology statement: Real-time PCR assays are designed to detect pathogens with clinical significance and analytical sensitivity and specificity greater than 99%.

Limitations: While these assays are very sensitive and specific, theoretically these assays could detect pathogens not listed, resulting in a false positive.

In addition, while these assays are very specific, there may be target pathogen sequences with unknown sequence variability which may not be detected, resulting in a false negative result.